Brookline Capital Acquisition Corp.
BCACW
NASDAQ Capital Market0.55
USD
+0.31
- -
CIK
0001814140
Return %
Stock
S&P500
1Y
52.69
18.21
3Y
-79.01
64.38
5Y
-79.01
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- DE United States of America 10022
- IPO Date
- Feb 22, 2021
- CIK
- 0001814140
- Similar Companies
- Business
- Brookline Capital Acquisition Corp. is a special purpose acquisition company (SPAC) formed to facilitate mergers, capital stock exchanges, asset acquisitions, stock purchases, recapitalizations, reorganizations, or other business combinations primarily within the life sciences sector. Incorporated in 2020 and headquartered in New York, New York, the company does not have significant operations of its own but focuses on acquiring and merging with businesses in medical and biomedical fields. The company’s primary activities involve raising capital through public offerings and private placements to support its acquisition targets. Recent major developments include its definitive business combination agreement with Apexigen Inc., a biomedical company, indicating its active pursuit of growth via merger transactions in the life sciences industry. As a SPAC, Brookline Capital Acquisition Corp. acts as a vehicle to bring private companies public through reverse merger transactions, leveraging its raised capital to support these initiatives. The company also has executed capital-raising efforts through public offerings and private placements that facilitate its acquisition strategy. Brookline Capital Acquisition Corp. operates domestically with a focus on the U.S. market but aims to engage companies with innovative medical and biotech products or technologies. Its role is strategic, investment-driven, and focused on creating stakeholder value through targeted acquisitions and mergers within its chosen sector, leveraging its position as a blank check company in capital markets to drive business combination opportunities in life sciences and biomedical industries. Its headquarters are located at 600 Lexington Avenue, New York, NY. The company’s recent activities underscore its commitment to expanding in the life sciences sector via strategic acquisitions and capital market transactions since its formation in 2020.